芦可替尼乳膏治疗特应性皮炎的长期安全性与疾病控制:两项3期研究结果
两项双盲3期研究评估芦可替尼乳膏治疗特应性皮炎的长期安全性与疾病控制。患者维持每日两次0.75%/1.5%方案或从赋形剂重新随机分配,52周内不良事件发生率分别为67.4%/62.6%/53.5%/57.6%,第52周74.1%至77.8%患者达到研究者整体评估0/1,平均受累体表面积低(1.4%-1.8%)。
要点
- 52周内不良事件发生率0.75%/1.5%芦可替尼乳膏组为67.4%/62.6%,赋形剂转0.75%/1.5%组为53.5%/57.6%。
- 最常见不良事件为上呼吸道感染(10.3%/11.4%/5.9%/7.1%)和鼻咽炎(8.9%/9.9%/7.9%/14.1%)。
- 第52周74.1%至77.8%患者达到研究者整体评估0/1,平均受累体表面积低(1.4%-1.8%)。
核心结论
- 在44周按需治疗期间,芦可替尼乳膏显示出有效的疾病控制与耐受性;低芦可替尼血浆浓度与反映已知风险因素的安全性结果提示,具有生理意义的全身Janus激酶抑制极不可能。
研究设计与样本
- 两项双盲3期特应性皮炎研究(NCT03745638/NCT03745651),患者最初随机接受每日两次0.75%/1.5%芦可替尼乳膏,在44周长期安全性期间维持方案(按需治疗);赋形剂组患者在第8周按1:1重新随机分配至任一芦可替尼乳膏浓度。
主要发现
- 52周内不良事件发生率在0.75%/1.5%芦可替尼乳膏/赋形剂转0.75%芦可替尼乳膏/赋形剂转1.5%芦可替尼乳膏组分别为67.4%/62.6%/53.5%/57.6%(n=426/446/101/99)。
- 最常见不良事件为上呼吸道感染(10.3%/11.4%/5.9%/7.1%)和鼻咽炎(8.9%/9.9%/7.9%/14.1%)。
- 大多数不良事件被认为与治疗无关,应用部位反应不常见(3.8%/1.8%/1.0%/1.0%)。
- 整个长期安全性期间实现疾病控制;第52周74.1%至77.8%患者达到研究者整体评估0/1,平均受累体表面积低(1.4%-1.8%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 长期安全性期间无对照治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Ruxolitinib cream demonstrated safety and efficacy over 8 weeks in 2 double-blind phase 3 atopic dermatitis studies (NCT03745638/NCT03745651). OBJECTIVE: To evaluate long-term safety (LTS) and disease control with ruxolitinib cream. METHODS: Patients initially randomized to twice-daily 0.75%/1.5% ruxolitinib cream maintained their regimen during the 44-week LTS period (as-needed treatment). Patients on vehicle were rerandomized (1:1) at week 8 to either ruxolitinib cream strength. Safety and disease control (Investigator's Global Assessment score 0/1 and affected body surface area) were assessed. RESULTS: Over 52 weeks, adverse events were reported in 67.4%/62.6%/53.5%/57.6% of patients in 0.75%/1.5% ruxolitinib cream/vehicle to 0.75% ruxolitinib cream/vehicle to 1.5% ruxolitinib cream groups (n = 426/446/101/99). Most common adverse events were upper respiratory tract infection (10.3%/11.4%/5.9%/7.1%) and nasopharyngitis (8.9%/9.9%/7.9%/14.1%). Most adverse events were considered unrelated to treatment. Application site reactions were infrequent (3.8%/1.8%/1.0%/1.0%). Disease control was achieved throughout the LTS; 74.1% to 77.8% of patients had Investigator's Global Assessment 0/1 at week 52, and mean affected body surface area was low (1.4%-1.8%). LIMITATIONS: LTS had no control treatment. CONCLUSION: During 44 weeks of as-needed treatment, ruxolitinib cream demonstrated effective disease control and tolerability; low ruxolitinib plasma concentrations alongside safety findings reflecting known risk factors suggest physiologically meaningful systemic Janus kinase inhibition is highly unlikely.
引用
- Papp K, Szepietowski JC, Kircik L, et al. Long-term safety and disease control with ruxolitinib cream in atopic dermatitis: Results from two phase 3 studies. J Am Acad Dermatol. 2022. PMID: 36574595. doi:10.1016/j.jaad.2022.09.060
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。